Humana and drug maker examine COPD
he collaboration between Boehringer Ingelheim and Humana is designed to address these needs as healthcare delivery and treatment programs evolve
Humana and Boehringer Ingelheim Pharmaceuticals have announced a multi-year collaboration to address key questions regarding treatment and healthcare costs for patients with chronic obstructive pulmonary disease (COPD), cardiovascular disease, and other disease states.
The collaboration will include input from Humana clinical experts so that the study results can provide actionable information for benefit design and outreach. Boehringer Ingelheim will also have access to payer data.
“Payers are in need of better information on appropriate treatment among their members for key disease areas, in order to design appropriate and adequate benefit plans,” William Fleming, PharmD, president of Humana Pharmacy Solutions, says. “Pharmaceutical companies need to better understand real-world application and outcomes of their medications to provide the best targeted care for afflicted patients. The collaboration between Boehringer Ingelheim and Humana is designed to address these needs as healthcare delivery and treatment programs evolve.”
The American Lung Association reports that more than 12 million Americans are living with COPD, as well as an estimated 12 million more undiagnosed cases. According to the Centers for Disease Control and Prevention, half of all Americans meet at least one of the risk factors for cardiovascular disease: high blood pressure, high LDL cholesterol, or smoking.
“The partnership is designed to address common questions that managed care and hospital decision makers are interested in, through well designed and implemented studies that may be published in peer reviewed venues,” Dr. Fleming says.
Addressing the overall health of the entire population will be critical to providing cost-effective and efficient healthcare in the United States.
“This will involve all the players in healthcare delivery,” he says. “We believe that collaborations among payers and health products companies will help to better address the needs of the population and impact the overall outcomes by disease area.”
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
